ProPhase Labs Files 8-K on Security Holder Vote
Ticker: PRPH · Form: 8-K · Filed: Jun 21, 2024 · CIK: 868278
| Field | Detail |
|---|---|
| Company | Prophase Labs, INC. (PRPH) |
| Form Type | 8-K |
| Filed Date | Jun 21, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0005 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
ProPhase Labs shareholders voted on key company matters on June 20th.
AI Summary
On June 20, 2024, ProPhase Labs, Inc. filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing indicates a meeting or vote took place concerning company governance or strategic decisions.
Why It Matters
This filing signals a significant event where shareholders had the opportunity to influence the company's direction, potentially impacting future operations and stock value.
Risk Assessment
Risk Level: medium — Shareholder votes can lead to significant changes in company leadership or strategy, introducing uncertainty.
Key Players & Entities
- ProPhase Labs, Inc. (company) — Filer of the 8-K report
- June 20, 2024 (date) — Date of the earliest event reported
FAQ
What specific matters were submitted for a vote by ProPhase Labs' security holders?
The filing does not specify the exact matters submitted for a vote, only that such matters were presented.
When did the event related to the security holder vote occur?
The earliest event reported in the filing occurred on June 20, 2024.
What is the Commission File Number for ProPhase Labs?
The Commission File Number for ProPhase Labs is 000-21617.
Where is ProPhase Labs, Inc. incorporated?
ProPhase Labs, Inc. is incorporated in Delaware.
What is the principal executive office address for ProPhase Labs?
The principal executive office is located at 711 Stewart Avenue, Suite 200, Garden City, New York 11530.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-06-21 16:30:27
Key Financial Figures
- $0.0005 — ch Registered Common Stock, par value $0.0005 PRPH Nasdaq Capital Market Indic
Filing Documents
- form8-k.htm (8-K) — 41KB
- 0001493152-24-024751.txt ( ) — 210KB
- prph-20240620.xsd (EX-101.SCH) — 3KB
- prph-20240620_lab.xml (EX-101.LAB) — 33KB
- prph-20240620_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 PROPHASE LABS, INC. (Exact name of Company as specified in its charter) Delaware 000-21617 23-2577138 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 711 Stewart Avenue , Suite 200 Garden 11530 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (215) 345-0919 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions ( see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities Registered Pursuant to Section 12(b) of the Exchange Act: Title of Each Class Trading Symbol Name of Each Exchange on Which Registered Common Stock, par value $0.0005 PRPH Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.07 Submission of Matters to a Vote of Security Holders. The final voting results of the matters voted on at the 2024 Annual Meeting of Stockholders of ProPhase Labs, Inc. (the "Company") are provided below. Proposal 1. Election of Directors Each of the nominees for election to the board of directors was elected to hold office for a one-year term and until their respective successors are elected and qualified by the following votes: Name For Withheld Broker Non- Votes Ted Karkus 13,777,271 149,634 3,397,472 Eleanor McBrier 13,035,907 890,998 3,397,472 Louis Gleckel, MD 12,973,504 953,401 3,397,472 Warren Hirsch 13,045,528 881,377 3,397,472 Proposal 2. Ratification of the Appointment of Independent Auditors The ratification of the appointment by the Company's board of directors of Morison Cogen LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was approved by the following vote: For Against Abstain Broker Non- Votes 17,298,184 21,782 4,411 N/A Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ProPhase Labs, Inc. By: /s/ Ted Karkus Ted Karkus Chairman of the Board and Chief Executive Officer Date: June 21, 2024